

Post Graduate Teaching  
*14 Oct 2020, BMEC*

# Medical Retina Emergencies

*Mr Randhir Chavan*  
*Consultant (MedRet), BMEC*



# GUIDELINES FOR THE MANAGEMENT OF COMMON MEDICAL RETINAL CONDITIONS IN EYE CASUALTY

## DIABETIC RETINOPATHY

### 1. Proliferative diabetic retinopathy

If a patient with known PDR (PRP done in past) is seen in eye casualty with new onset of decreased vision due to vitreous haemorrhage then patient needs urgent PRP + anti-VEGF. An urgent laser slot had been created in each routine PM laser list for retinopexy/PRP. Please find out if urgent PRP can be arranged in this slot over the next few days from Medical retina booking team. If no slot available then please discuss with Medical retina Consultant/fellow. Also leave the notes in the medical retina tray in Eye Casualty INDICATING PATIENTS MEDICAL RETINA CONSULTANT IN CHARGE and the fact that patient NEEDS URGENT PRP+anti-VEGF. Urgent fax to LOCAL MEDICAL RETINA UNIT informing them about this episode and to arrange further follow up. Fax to be done by Eye Casualty admin staff.

If the vitreous haemorrhage is dense with poor fundal view and a retinal tear or detachment cannot be excluded then a B scan should be performed on the same day. Consider referral to VR service depending on the B-scan findings. If retina is flat and no urgent VR intervention required then forward notes to the consultant in charge or LOCAL EYE UNIT.

## URGENT PRP MANAGEMENT (Same day PRP)


### 1. New vessels on the iris (Rubeosis iridis; NVI)

a) NVI with normal IOP - **same day** PRP (aim for 1500 spots) and inform Medical retina fellow /Consultant for urgent intravitreal Avastin (within a week) and further management.


[www.bhameyecas.org](http://www.bhameyecas.org)

# Common Medical Retina Conditions in Eye Casualty


## The big '3'



- AMD
  - Wet and Dry forms affect 25% of over 60s




- Diabetic Retinopathy
  - Overall affects 40% Diabetic patients



- Retinal Vein Occlusions
  - CRVO affects 0.5% of over 65s
  - BRVO 2-3 times higher

# Choroidal neovascularization (CNV) *Neovascular AMD.*


- Metamorphopsia is initial symptom



Pinkish-yellow subretinal lesion  
with fluid

Subretinal blood or lipid

- Massive haemorrhage and suspected CNVM.
- VR opinion to consider any surgical intervention (tPA +gas)



**Sub – retinal Heam**

Bright red

Scalloped borders

Better prognosis with t-PA + gas




**Sub-RPE Heam**

Dard red – brown

Smooth & well demarcated borders

Poor prognosis



# SUSPECTED CNV – Casualty management

- New referral from OPTICIAN - Send referral to Medical Retina Office for FAST TRACK MACULAR CLINIC appointment in 2 weeks
- Known case of CNVM from any aetiology with new onset distortion - Send notes to Consultant in charge or LOCAL UNIT for further review.
- ***Massive haemorrhage and suspected CNVM with 1 week history - VR opinion to consider any surgical intervention (tPA +gas)***


## Diabetic retinopathy


- Last 20 years DM: **1.4 → 3.5 million.**
- **1 in every 16** people having diabetes (diagnosed and undiagnosed).
- Diabetes prevalence in the UK is estimated to rise to 5 million by 2025.
- ***Sandwell and West Birmingham - Total Diabetics increased from 16,410 to 29,688 from 2008 to 2018 ( an increase of 81%)***

# Data from DESP

|                           | Whole Screening Programme |        |        |        | Sandwell and West Birmingham CCG |      |       |       |
|---------------------------|---------------------------|--------|--------|--------|----------------------------------|------|-------|-------|
|                           | 2008                      | 2012   | 2018   | 2019   | 2008                             | 2012 | 2018  | 2019  |
| Total Px screened         | 77283                     | 101730 | 127859 | 128984 | n/a                              | n/a  | 29688 | 29937 |
| Referred to ophthalmology | 12364                     | 12788  | 3289   | 2641   | n/a                              | n/a  | 1047  | 859   |
| referred to surveillance  | n/a                       | n/a    | 3583   | 3497   | n/a                              | n/a  | 815   | 735   |
| R0                        | 49056                     | 67967  | 97580  | 98092  | n/a                              | n/a  | 22694 | 22828 |
| R1                        | 20748                     | 27751  | 25324  | 26649  | n/a                              | n/a  | 5765  | 6093  |
| R2                        | 586                       | 935    | 811    | 685    | n/a                              | n/a  | 187   | 158   |
| R3( A & S)                | 4940                      | 1249   | 891    | 597    | n/a                              | n/a  | 245   | 168   |
| of which R3A:             | n/a                       | n/a    | 533    | 401    | n/a                              | n/a  | 162   | 117   |
| U                         | 1953                      | 3828   | 3206   | 2927   | n/a                              | n/a  | 787   | 762   |

# R3 (A&S) in Birmingham area in 2008 and 2018






# Proliferative diabetic retinopathy

- Affects 5-10% of diabetics
- Type 1 at increased risk (60% after 30 years)

## Neovascularization

- Flat or elevated




Neovascularization of disc = NVD

Neovascularization elsewhere = NVE


# High risk Proliferative diabetic retinopathy



NVD > 1/3 disc in area



Less extensive NVD +  
haemorrhage



NVE > 1/2 disc in area  
+ haemorrhage

# Same day PRP

- **New vessels on the iris** (Rubeosis iridis) - Aim for 1500 spots  
Inform MR team for urgent IV anti-VEGF – Follow pathway
- **High-risk proliferative diabetic retinopathy** (NVD  $\geq$  1/3 disc area;  
NVD with VH; NVE  $\geq$  1/2 disc area with VH).
- **PDR in pregnancy**
- **Only eye**

# General principles of PRP

- Aim for 1000 – 1500 burns /session
- Inferior first → temporal → superior → nasal
- At least 2DD clear area from disc nasally (Temporal visual field)
- High Risk PDR / NVI – Aim for 2500–5000 / 500 $\mu$ m burns over 2 sessions

|                             | DRS / ETDRS        | Current                          |
|-----------------------------|--------------------|----------------------------------|
| Spot size                   | 500 $\mu\text{m}$  | 200 – 300 $\mu\text{m}$          |
| Power / Intensity           | Grey/white         | Gray – reduce power in periphery |
| Duration                    | 100ms              | 10 – 50 ms                       |
| Spacing                     | 0.5 – 1 burn apart | 1-1.5 burn apart                 |
| Direct treatment to vessels | NVE                | Avoid                            |

**Appendix 1: Table of commonly available laser contact lens magnifications and fields of view**


| Name of lens         | Field of view (in degrees) | Image magnification | Laser spot magnification |
|----------------------|----------------------------|---------------------|--------------------------|
| Area Centralis®      | 70-84                      | 1.06                | X0.94                    |
| Mainster focal/grid® | 90-121                     | 0.96                | X1.05                    |
| TransEquator®        | 110-132                    | 0.70                | X1.44                    |
| Quadraspheric®       | 120-144                    | 0.51                | X1.97                    |
| Superquad 160®       | 160-165                    | 0.50                | X2                       |
| Mainster PRP 165®    | 165-180                    | 0.51                | X1.96                    |

# Most important bit

- Fluence = (power x time)/area
- Fluence required to produce a burn is less with shorter pulse duration (shorter time)
- Shorter pulse duration – less damage
- Less fluence – less damage to outer retina /RPE
- Minimal collateral damage

# The big '3'

## Retinal Vein Occlusions




### ***Systemic:***

Increasing age

Diabetes

### **Hypertension**

Abnormalities of coagulation



### ***Ocular:***

**Raised intraocular pressure**

Periphlebitis

# Signs of ischaemic CRVO




- VA < 6/60
- APD - marked
- Marked venous tortuosity and engorgement
- Extensive retinal haemorrhages
- Variable cotton wool spots
- Severe disc oedema
- Macular ischaemia
- Very poor prognosis
- Rubeosis irides in 50%

# CENTRAL AND BRANCH RETINAL VEIN OCCLUSION

- Check BP and BM in Eye Casualty
- Clinically differentiate Ischaemic from Non-ischaemic CRVO
- Check for rubeosis
  
- New referral from OPTICIAN - Send referral to Medical Retina Office for FAST TRACK VEIN OCCLUSION CLINIC appointment.


# Central retinal artery occlusion ( CRAO )



- VA < 6/60; APD – marked; Very poor prognosis
- Retinal whitening; ‘Cherry-red spot’ at macula
- Sludging and segmentation of blood column (cattle-trucking)




# Branch retinal artery occlusion ( BRAO )




- VA - variable
- APD - mild or absent
- Retina whitening
- Arteriolar narrowing

# Types of emboli




# Cholesterol emboli (Hollenhorst plaques)



- Multiple, bright, refractile crystals
- Often located at arteriolar bifurcations
- Frequently asymptomatic

# Fibrinoplatelet emboli



- Multiple, dull grey particles
- Occasionally fill entire lumen
- May cause amaurosis fugax and occasionally permanent obstruction

# Calcific emboli



- Usually single, white and close to disc
- May cause permanent obstruction

# Referral Pathway to TIA / Stroke Clinic

- Embolus
  - CRAO
  - VA / Field loss
  - transient
  - fluctuating (no disc swelling)
- Check BP**

## Complete TIA form

- email low risk
- Phone high risk
- scoring points  $\geq 4$
- high risks factors

**Refer Stroke patient to stroke team**

|   |    |             |             |      |
|---|----|-------------|-------------|------|
| Patient Details   |    | Name:       | DOB:        | Age: |
| Address:  |    |             |             |      |
| Telephone:  |    | RXK Number: | NHS Number: |      |
| Referral made by:                                       |    |             | GP details: |      |
| GP:   | AE | BMEC        | others      |      |
| Contact number of referring doctor (direct if possible) |    |             |             |      |

|  |  |
|--|--|
| <b>Timings (please complete in full)</b>           |  |
| Date and time of index event                       |  |
| Date and time of assessment                        |  |
| Date and time of receipt of referral (leave blank) |  |

|   |       |      |              |
|---|-------|------|--------------|
| <b>Clinical Features (tick as appropriate):</b> | Right | Left |              |
| Hemiparesis – arm and / or leg weakness         |       |      | Dysphasia    |
| Hemisensory loss                                |       |      | Dysarthria   |
| Loss of vision one eye                          |       |      | True Vertigo |
| Loss of visual field                            |       |      | Diplopia     |
| Inco-ordination / ataxia                        |       |      |              |

|                      |            |            |
|----------------------|------------|------------|
| <b>Brief History</b> | <b>BP:</b> | <b>BM:</b> |
|                      |            |            |

|   |                 |    |  |  |  |
|---|-----------------|----|--|--|--|
| <b>Past Medical History – Tick all that apply</b> |                 |    | <b>Recent investigations (if applicable)</b> |  |  |
| Atrial Fibrillation                               | Smoker          | Ex | FBC  |  |  |
| Hypertension                                      | PVD             |    | UF   |  |  |
| Angina  | DM              |    | Cholesterol                                  |  |  |
| Previous MI                                       | Hyperlipidaemia |    | ECG  |  |  |
| CABG  | Heart failure   |    |  |  |  |

|                           |                             |
|---------------------------|-----------------------------|
| <b>Usual Medications:</b> | <b>Medications Started:</b> |
|                           |                             |

|   |   |                                    |  |
|---|---|------------------------------------|--|
| <b>ABCD2 Score : TOTAL</b>                  |   | <b>HIGH RISK CLINICAL FEATURES</b> |  |
| Age > 60 years                              | 1 |                                    |  |
| Systolic BP > 140 and /or diastolic BP > 90 | 1 |                                    |  |
| <b>Clinical Features</b>                    |   |                                    | BP > 180/100   |
| Unilateral weakness                         | 2 |                                    | Crescendo TIAs (>2 events in a week)                 |
| Speech disturbance without weakness         | 1 |                                    | Patient on warfarin or newer anticoagulants          |
| Other                                       | 0 |                                    | Young patients (<50) with TIA symptoms and neck pain |
| <b>Duration of Symptoms:</b>                |   |                                    | Patients with prosthetic valves                      |
| >60 minutes                                 | 2 |                                    | Fluctuating symptoms                                 |
| 10-59 minutes                               | 1 |                                    | Current or known paroxysmal atrial fibrillation      |
| <10 minutes                                 | 0 |                                    |  |

**REMEMBER TO GIVE aspirin 300mg stat, if no contraindication AND ADVISE NOT TO DRIVE**

SWBH TIA clinic Referral Form – email to [swbh.tiaclinic@nhs.net](mailto:swbh.tiaclinic@nhs.net)

- CORRECT CONTACT NUMBER
- INTERPRETER?

**TO SPEAK TO TIA CLINIC NURSE - 0121 507 3766**

**STROKE TEAM CONTACT DETAILS**

Stroke Alert Nurse Specialist (24/7): 0779 224 8506

Stroke SpR: bleep 6020 (note out-of-hours bleep held by Sandwell SpR on call)

If ABCD2 score 4 and above  
OR  
High risk clinical features (\*)



**HIGH RISK**

**HIGH RISK FEATURES (\*):** patient to be referred as high risk whatever the ABCD2.


- Fluctuating symptoms
- Current or known paroxysmal atrial fibrillation
- BP > 180/100
- Crescendo TIAs (>2 events in a week)
- Patient on warfarin/rivaroxaban/dabigatran/apixaban/edoxaban
- Young patients with TIA and neck pain (<50)
- Patients with prosthetic valves

If in doubt OR if patient has ongoing symptoms or signs please discuss with stroke SpR or Consultant via SWBH switchboard



If you suspect that the patient had a stroke, follow the stroke pathway Please REFER stroke patients directly to the Stroke Team for admission

# The Medical Retina Emergency Unmissables

- Untreated Malignant Hypertension
- Post-operative Endophthalmitis
- Rubeosis Iridis



**BP=230/126**



**BP= 138/88**

**Untreated MHT:**  
88% mortality in 2 yrs  
**Treated MHT:**  
80% survival in 5 yrs


Check BOTH fundi...  
Check BP.....

Same day send  
patient to main  
casualty, not to GP

# Endophthalmitis



- Pain and marked visual loss
- Corneal haze, fibrinous exudate and hypopyon



- Absent or poor red reflex
- Inability to visualize fundus with indirect ophthalmoscope



# Acute Post –op bacterial endophthalmitis

Incidence - about 1:1,000



## Common causative organisms

- *Staph. Epidermidis; aureus*
- *Pseudomonas sp.*

## Source of infection

Patient's own external bacterial flora is most frequent culprit


## Intravitreal Injections

### Gram +ve

Vancomycin  
( 1 mg / 0.1 ml )

### Gram -ve

Amikacin  
( 0.4 mg / 0.1 ml )  
or  
Ceftazidime  
( 2 mg / 0.1 ml )



## SUMMARY

- FAMILIARISE YOURSELF WITH THE LOCAL GUIDELINES FOR VITREOUS TAP AND INTRAVITREAL ANTIBIOTICS
- VITREOUS TAP AND INTRAVITREAL INJECTIONS AT BMEC ARE DONE IN A CLEAN ROOM
- USE A 23G BLUE NEEDLE AND 3 ML SYRINGE TO PERFORM VITREOUS TAP – IF DRY TAP, REPLACE 3ML SYRINGE WITH A 5ML SYRINGLE
- AFTER VITREOUS TAP, INJECT INTRAVITREAL ANTIBIOTICS
- PERFORM AC TAP WITH A 1 ML SYRINGE WITH PLUNGER REMOVED
- REPLACE NEEDLES IN SYRINGES WITH A LUER LOCK CAP
- SEND SAMPLES TO MICROBIOLOGY DEPARTMENT FOR CULTURE SENSITIVITY + / PCR TEST

# PATIENTS WEARING FACE MASKS DURING INTRAVITREAL INJECTIONS MAY BE AT A HIGHER RISK OF ENDOPHTHALMITIS

AMIR HADAYER, MD,\*† ALON ZAHAVI, MD,\*† EITAN LIVNY, MD,\*† ORLY GAL-OR, MD,\*† ASSAF GERSHONI, MD,\*† KARIN MIMOUNI, MD,\*† RITA EHRLICH, MD\*†

---

**Purpose:** To investigate the safety of face masks worn by patients during intravitreal injections.

**Methods:** A prospective, qualitative, interventional study performed in a tertiary university hospital. Healthy volunteers were asked to wear three different professional surgical face masks while air leaks around the eyes were monitored. Three types of masks were investigated as follows: 1) surgical face mask with four tying strips, 2) surgical face mask with elastic ear loops and 3) 2200 N95 tuberculosis particulate face mask. For each session the periocular area was inspected for air leak during normal respiration, speech, and deep respiration. Detection of air leak was performed using the following two professional thermal cameras: FLIR A310—thermal camera and EyeCGas 2.0—super sensitive infrared camera used for detection of minute fugitive emissions of industrial gases.



**Results:** Ten healthy volunteers were enrolled in this study. The experiment was repeated 45 times for each camera; 3 times for each of 3 mask types, on 5 volunteers, for a total of 90 trials. Air jets were detected originating from the superior edges of the masks radiating toward the eyes in 81% (73/90) of cases in total; 71% (32/45) with the FLIR camera and 91% (41/45) with the OPGAL camera. Air leaks were detected with all investigated mask types.

**Conclusion:** Patients wearing face masks during intravitreal injections may be at a higher risk of endophthalmitis. Until further data are available, we recommend verifying proper face mask fitting and either taping the upper edges of the face masks with a medical adhesive tape or using an adhesive surgical drape around the injected eye.


**RETINA** 40:1651–1656, 2020

---

# Rubeosis Iridis



## BMEC Neovascular Glaucoma Treatment Protocol



Anti-VEGF  
reverses Rubeosis

\* Aims for both MedRet and Glaucoma Opinions - same day / next day (Mon-Fri)  
 \*\* Paracentesis (a temporarily measure) can be performed ad hoc pre- or /and post-anti-VEGF injection if IOP is refractory when cyclodiode procedure is not immediately available.

### Weekends:

Avastin (=Bevacizumab) can be obtained from on-call pharmacist (completed online DTC form **OR** yellow Avastin paper form to be handed in to BMEC pharmacy on Monday)

**NB: order for Bevacizumab 5mg/0.2ml (one vial) as pharmacist in main hospital site only recognises generic name**


# Re-audit on treatment outcomes in Eyes with Initial Rubeosis only and Eyes with Neovascular Glaucoma

Rinoza Bafiq, Randhir Chavan,  
Mrs Peck-Lin Lip


# Important points from NVI Re-audit

- **55% (27/49 eyes) had vision worse than 6/60 at presentation . 64% of these patients maintained their vision**
- **62% of patient has PRP in 2 weeks of presentation**
- **67.34% of patients has IVI in 2 weeks of presentation. 32% of these patients vision improved**

# V/A Improvement: Comparing Audit to Reaudit



# V/A Improvement: Comparing Audit to Reaudit



# Some examples of management plans:

- Left Neovascular glaucoma with iris new vessels, high IOP, Hazy decompensated cornea and hazy fundal view showing signs of a CRVO with haem. ++
- Plan: URGENT PRP Laser to left eye as soon as cornea clears.
- ***Notes to Glaucoma & Medical Retina Consultants.***
- **PL at presentation – No PL at last follow up**

# Some examples of management plans:

- Has R rubeosis, retinal peripheral haemorrhages
- Gonio - RE total synechial angle closure and NVA. LE – PAC
- Imp - R NVG due to ischaemic CRVO; L PAC
- Plan: Start monopost BEs, cosopt pf bd RE, Listed for PI LE
- ***See in 2/12***; GP to investigate and treat vascular risk factors.
  
- **6/24 at presentation – PL at last follow up**

# Some examples of management plans:

- Saturday clinic
- right eye rubeosis ,IOP high ,gonio zipped angle in at least 2 quadrants;listed for X2 PRP sessions RIGHT EYE
- refer to medical retina for further assessment and possible IVI Avastin
- ***6/36 at presentation – PL at last follow up***

- B/L PDR with rubeosis LE
- IOP RE 21mmHg LE 36mmHg
- PO diamox 500mg stat; g. latanoprost LE stat
- For B/L PRP today given good fundal view.
- Please check IOP later. Please start patient on g. latanoprost LE until next review.
- ***F/Up in Eye Cas will need more laser***
- ***6/18 PH 6/12at presentation – 6/60 with Tube at last follow up***

# Good examples:

- Left neovascular glaucoma secondary to PDR
- Plan: IV Diamox and anti-Glaucoma drops
- ***OCT both eyes-Both eyes CMO-Right , < 400microns, Left > 400 microns***
- ***W/L Left Lucentis x 03 x 04 weeks apart-1 st today, 2 further injections 4 weeks apart booked***
- ***Right pre and post injection G.Apraclonidine 1% stat please***
- Left PRP x 2 sessions
- D/W MR and Glaucoma Consultants – Agree with plan and review Glaucoma clinic 1 week
- ***6/60 with PH 6/18 at presentation – 6/9 with tube at last follow up***

# Good examples:

- Left rubeotic glaucoma, Left PRP today. and to be repeated in 2 weeks. D/W MR Consultant - Left Avastin on Monday confirmed
- Left Avastin x2 one month apart.
- ***6/36 at presentation – 6/60 at last follow up***

# Good examples:

- Seen in Glaucoma Clinic by fellow: LE CRVO with NVE inferiorly and NVI; IOP 40
- D/W MR Consultant - Urgent LE PRPx2 and IVI Avastin
- IVI done next day; Cyclodiode in 1 week; PRP in 2 weeks
- ***6/60 at presentation – 6/24 at last follow up***

# Good examples:

- Referred urgently from Optegra
- consultation for right cataract at Optegra; IOP 64 - NVG
- Avastin injection arranged next few days
- ***6/12 at presentation – 6/9 with tube at last follow up***


# Good examples:

- Right NVI with elevated IOP (60mmHg)
- Seen by MR and Glaucoma Consultant on the day – Urgent Cyclodiode and PRP today
- For urgent IVI avastin tomorrow
- ***6/24 with pin hole 6/18 at presentation – 6/12 with PH 6/9 with Tube at last follow up***

# Subgroup analysis: Presenting VA $\geq 6/12$

- 12 / 49 eyes (24.45%) at presentation were  $\geq 6/12$
- 58% received PRP same day and 83.3% received within 2 weeks
- 66.6% received IVI within 2 weeks
- 58% maintained their vision till last follow up

## BMEC Neovascular Glaucoma Treatment Protocol



\* Aims for both MedRet and Glaucoma Opinions - same day / next day (Mon-Fri)  
\*\* Paracentesis (a temporarily measure) can be performed ad hoc pre- or /and post-anti-VEGF injection if IOP is refractory when cyclodiode procedure is not immediately available.

### **Weekends:**

Avastin (=Bevacizumab) can be obtained from on-call pharmacist (completed online DTC form **OR** yellow Avastin paper form to be handed in to BMEC pharmacy on Monday)

**NB: order for Bevacizumab 5mg/0.2ml (one vial) as pharmacist in main hospital site only recognises generic name**

## Guidance working in BMEC eye casualty:

- Consultant / senior cover for advice
- BMEC departmental protocols
- Subspecialty clinics nearby (medret)

### Urgent protocols

- Endophthalmitis protocol
- Neovascular Glaucoma protocol

### Fast-track Medret clinics

- Macula, RVO

[www.bhameyecas.org](http://www.bhameyecas.org)